In Episode 2, doctors examine how effectively managing both low and intermediate risk NMIBC continues to evolve. Given both the global BCG shortage as well as the unmet need for more effective therapies, innovative strategies and trials are required to enhance our patient’s clinical outcomes as well as to decrease the well described morbidity and costs associated with current NMIBC therapies.
